MKMohammad Keramatipour

Mohammad Keramatipour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Keramatipour has a total of 217 co-authors. Here are the top co-authors by number of shared publications:

  • Zahra Golchehre

    Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

    10 shared publications
  • Saeed Talebi

    Department of Medical Genetics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

    7 shared publications
  • Mohammad Saberi

    Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran

    6 shared publications
  • Mona Entezam

    Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    6 shared publications
  • Arezou Karamzade

    Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    5 shared publications
  • Mostafa Asadollahi

    Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    5 shared publications

Latest Publications

  • A case report of ultra-rare SMARCD2 deficiency and review of the literature

    by Zahra Golchehre, Shahrzad Fallah, Yeganeh Eshaghkhani, Zahra Chavoshzadeh, Nasrin Esfandiar, Bibi Shahin Shamsian, Arezou Karamzade, Mohammad Saberi, Mohammad Keramatipour

    • 1 January 2026
      • Vol. 20  (1) , 79-84
    Open Access

    Decoding the Genetic Enigma: A Case Study on Congenital Anomalies with Developmental Delay and 9q Duplication Unveiled Via Comprehensive Whole Exome Sequencing and Cytogenetic Analysis

    by Reyhaneh Dehghanzad, Mohsen Aghajanpour Mir, Zahra Golchehre, Mostafa Asadollahi, Roghayeh Rahbar Parvaneh, Behnoosh Tasharrofi, Abbas Shakoori Farahani, Mohammad Keramatipour

    Approximately 3% of newborns worldwide are affected by Congenital Anomalies (CAs) with or without Intellectual Disability (ID)/Developmental Delay (DD), often caused by genetic factors such as single-gene disorders or chromosome aberrations. Whole Exome Sequencing (WES) has become a highly effective first-tier test for identifying these genetic factors, detecting both Copy Number Variations (CNVs) and Single Nucleotide Polymorphisms (SNPs)/Insertion/Deletion Polymorphisms (INDELs), while conventional cytogenetic analysis can provide additional valuable information to confirm results where applicable. The proband DNA was extracted and subjected to WES. Genetic variants were analyzed using the Genome Analysis Toolkit (GATK) following the American College of Medical Genetics and Genomics (ACMG) guidelines. Additionally, karyotyping of the child and her parents was conducted with high-resolution CTG banding after harvesting conventional cell cultures and performing Giemsa banding on metaphase spreads of cultured leukocytes. This study describes a patient with microcephaly, mild intellectual disability, and specific facial features, where initial WES did not identify any causative SNPs/INDELs. However, subsequent WES-based analysis for CNVs revealed the presence of dup (9) (q21.11q22.32). Further chromosomal analysis uncovered unique karyotypes for the patient [46, XX, t (5; 9) (p15.1; q22.1), add (14) (p11.1)] and her father [46, XY, t (5;9)(p15.1;q22.1)], and a normal karyotype for the mother. The present study confirms the effectiveness of utilizing WES-based analysis of CNVs and SNPs/INDELs as the primary diagnostic test for identifying patients with CAs/ID/DD.

  • Open Access

    Autosomal recessive frameshift variant broadens HECW2-related disease spectrum

    by Reyhaneh Dehghanzad, Yeganeh Eshaghkhani, Mohammad Saberi, Maryam Jamshidifar, Parvaneh Karimzadeh, Mohammad Keramatipour

  • Open Access

    BCKDK gene mutations as a rare condition responsible for comorbid neurodevelopmental delay, autism, and epilepsy: a case series of four patients

    by Parvaneh Karimzadeh, Maryam Kachuei, Hossein Najmabadi, Mohammad Keramatipour, Mohammad Rezazadeh, Behnoosh Tasharrofi, Fatemeh KamaliTabar

    Introduction: Mutations in the branched-chain keto-acid dehydrogenase kinase gene (BCKDK), leading to low plasma branched-chain amino acids (BCAAs) levels, have been reported as a contributor to comorbid intellectual disability, autism, epilepsy, and neurodevelopmental delay (NDD). Due to the rarity of knowledge about these mutations, the current case series aims to introduce four confirmed cases. Methods: This case series study analyzed children from a neurometabolic clinic. Social and adaptive functions were assessed using the vineland social maturity scale (VSMS). Whole exome sequencing (WES) identified genetic variants filtered using population databases. Candidate variants were confirmed through Sanger sequencing and interpreted based on ACMG guidelines. Results: Four children of unrelated consanguineous families suffering from global NDD and autism were referred to our center. Neuroimaging assessments revealed negligible findings; thus, metabolic tests were sent, in which BCAAs were lower than normal limits. Therefore, genetic testing was done, and genetic variants compatible with BCKDK deficiency were detected. By initiating a BCAAs-rich regimen, the patients had significant improvements in psychomotor and speech development. Conclusion: The diagnosis of BCKDK deficiency should be suspected in patients with NDD and autism, and BCAA supplementation should be initiated as soon as diagnosis confirmation to prevent irreversible brain damage. The results emphasize that early diagnosis and dietary intervention by regulating plasma BCAA levels lead to the prevention of irreversible neurodevelopmental implications.


  • THPO promoter mutation: a familial study on congenital amegakaryocytic thrombocytopenia

    by Reyhaneh Dehghanzad, Roghayeh Rahbar Parvaneh, Maryam Jamshidifar, Zahra Khaffafpour, Roghayeh Rahimi Afzal, Sharareh Kamfar, Bibi Shahin Shamsian, Mohammad Keramatipour

    Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited bone marrow failure syndrome, which is characterized by a severe thrombocytopenia at birth without predictive stigmata and by a risk for progression into aplastic anaemia and myeloid malignancy. While CAMT primarily arises from mutations in the MPL gene, recent discoveries have linked biallelic THPO mutations to some CAMT cases. In addition, loss of function monoallelic mutations in this gene have been identified as causing benign autosomal dominant thrombocytopenia. In this study, we report a case of CAMT linked to a homozygous mutation in the promoter region of THPO (c.-324C>T, NM_000460.4). computational analysis indicates that this mutation suppresses the binding of some essential transcription factors to the THPO promoter. Family segregation analysis shows a significant reduction in platelet counts among carriers of the mutation. Our patient received allogeneic haematopoietic stem cell transplantation (HSCT) from her HLA-matched sister (MSD), who carries the mutation. After allogeneic HSCT, the patient showed 100% full donor chimerism, but 1 year after HSCT, despite full donor chimerism, the patient did not complete recover from platelet count, and she has received romiplostim several times. Understanding the MPL–THPO pathway is vital for managing CAMT, emphasizing the importance of identifying and assessing patients’ mutations for tailored treatment.

  • Open Access

    A comprehensive report of the clinical and mutational profiles of 30 Iranian malignant infantile osteopetrosis patients

    by Akbar Amirfiroozy, Maryam Naghinejad, Azim Rezamand, Hamid Farhangi, Zahra Golchehre, Hossein Jalali, Mohammad Taheri, Mohammad Keramatipour


  • Distinct neurological phenotypes associated with biallelic loss of NOTCH3 function: evidence for recessive inheritance

    by Behnoosh Tasharrofi, Ali Najafi, Elham Pourbakhtyaran, Susan Amirsalari, Golazin Shahbodagh Khan, Mahmoud Reza Ashrafi, Ali Reza Tavasoli, Mohammad Keramatipour, Morteza Heidari

    Background NOTCH3 variants are known to be linked to cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). However, some null NOTCH3 variants with homozygous inheritance cause neurological symptoms distinct from CADASIL. The aim of this study was to expand the clinical spectrum of this distinct condition and provide further evidence of its autosomal recessive inheritance. Methods and results Whole exome sequencing (WES) was performed on a proband who exhibited livedo racemosa, ataxia, cognitive decline, seizures, and MRI white matter abnormalities without anterior temporal pole lesions. Segregation analysis was conducted with Sanger sequencing. WES of the proband identified a novel homozygous NOTCH3 null variant (c.2984delC). The consanguineous parents were confirmed as heterozygous variant carriers. In addition, three heterozygous NOTCH3 null variants were reported as incidental findings in three unrelated cases analyzed in our center. Conclusion The findings of this study suggest an autosomal recessive inheritance pattern in this early-onset leukoencephalopathy, in contrast to CADASIL’s dominant gain-of-function mechanism; which is a clear example of genotype-phenotype correlation. Comprehensive genetic analysis provides valuable insights into disease mechanisms and facilitates diagnosis and family planning for NOTCH3-associated neurological disorders.


  • A novel missense variant in EIF2B5 identified in a consanguineous Iranian family with vanishing white matter disease and a brief review of the literature

    by Parisa Nourmohammadi, Mostafa Asadollahi, Arezou Karamzade, Yeganeh Eshaghkhani, Meisam Babaei, Zahra Golchehre, Seyedeh Roksana Taheri, Sepideh Hasani, Mahdieh Taghizadeh, Mohammad Keramatipour

    Vanishing of white matter (VWM) is a hereditary heterogeneous brain disorder that most often affects children. However, the onset of the disease varies from childhood to adulthood. VWM is caused by mutations in one of the five genes encoding subunits of the eukaryotic initiation factor eIF2B. In the current study, we aimed to determine the genetic cause of VWM in a large consanguineous Iranian family with three affected members. Next-generation sequencing was conducted on the proband to determine the underlying cause of VWM. The identified variant was validated by PCR-Sanger sequencing in the patient and was also segregated in his parents and two other affected members of the pedigree. The potential functional effects of this mutation within EIF2B5 were predicted by in silico analysis. We have also reviewed all EIF2B5 disease-causing variants and available clinical features of each patient reported in HGMD Professional 2022.2. A novel homozygous variant c.746T>G [p.Ile249Ser] was detected in EIF2B5 which was co-segregated with the disease in all affected family members in an autosomal recessive manner. All employed in silico prediction tools and 3D structure analysis for the novel mutation also supported the pathogenicity of this variant. Our study not only expanded the spectrum of the pathogenic variants in EIF2B5 but also presented a literature review on EIF2B5-related conditions that provide a comprehensive picture of the genetic nature of this gene and phenotypic variability in patients.

  • Intestinal hypomagnesemia in an Iranian patient with a novel TRPM6 variant: a case report and review of the literature

    by Farnaz Kamali, Mahnaz Jamee, John A. Sayer, Simin Sadeghi-Bojd, Zahra Golchehre, Reyhaneh Dehghanzad, Mohammad Keramatipour, Masoumeh Mohkam

    TRPM6 is predominantly expressed in the kidney and colon and encodes a protein containing an ion channel domain and a protein kinase domain. It is crucial for magnesium homeostasis and plays important roles in epithelial magnesium transport and the active magnesium absorption. In this study, we present a 70-day-old Iranian female patient from consanguineous parents with hypomagnesemia and secondary hypocalcemia. She presented with seizures 19 days after birth and refractory watery non-bloody diarrhea. She consequently had failure to thrive. Other features included hypotonia, wide anterior fontanel, ventriculomegaly, and pseudotumor cerebri following administration of nalidixic acid. She had severe hypomagnesemia and hypocalcemia which were treated with magnesium and calcium supplementation. Despite initial unstable response to supplemental magnesium, she eventually improved and the diarrhea discontinued. The patient was discharged by magnesium and calcium therapy. At the last follow-up at age 2.5 years, the patient remained well without any recurrence or complication. Genetic testing by whole-exome sequencing revealed a novel homozygous frameshift insertion–deletion (indel) variant in exon 26 of the TRPM6 gene, c.3693-3699del GCAAGAG ins CTGCTGTTGACATCTGCT, p.L1231Ffs*36. Segregation analysis revealed the TRPM6 heterozygous variant in both parents. Patients with biallelic TRPM6 pathogenic variants typically exhibit hypomagnesemia with secondary hypocalcemia and present with neurologic manifestations including seizures. In some patients, this is also complicated by chronic diarrhea and failure to thrive. Long-term complications are rare and most of the patients show a good prognosis with supplemental magnesium therapy.


  • New Presentation of CD27 Deficiency; Coronary Ectasia and COVID-19

    by Zahra Golchehre, Samin Sharafian, Nader Momtazmanesh, Zahra Chavoshzadeh, Abdollah Karimi, Hassan Abolhassani, Maryam Kazemi Aghdam, Koroush Vahidshahi, Seyedehatefeh Hashemimoghaddam, Farid Kosari, et al.

    CD27 is a costimulatory receptor involved in the maturation of the innate and adaptive immunity. CD27, through interaction with CD70, plays a role in the control of Epstein-Barr virus (EBV) infection. CD27 deficiency leads to an immune dysregulation disease characterized by EBV susceptibility. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might put patients with primary immunodeficiency at risk for adverse outcomes. Chromogenic in situ hybridization (CISH) study was performed to detect EBV in the lymphoma tissue. Genetic analysis of the patient was done with Whole Exome Sequencing and detected variant was confirmed with PCR-Sanger sequencing. Here we report a 20-month-old boy with CD27 deficiency who developed lymphoma and coronary artery ectasia and had been infected with SARS-CoV-2. Clinical and laboratory findings were incompatible with atypical Kawasaki syndrome or multisystem inflammatory syndrome in children (MIS-C). As CD27 deficiency is a rare immune defect, publishing clinical data about the identified patient(s) can shed light on our knowledge about the related phenotype and the spectrum of clinical manifestations associated with CD27 deficiency. Thus, our findings expanded the spectrum of manifestations beyond EBV infection, highlighting this unusual cardiac sequela that could be related to EBV infection, lymphoma, or an underlying disease.